IAVI acquires Aeras vaccine clinical programs & assets
Move will enable greater impact on the world’s two most urgent global health threats
Advancing New TB Vaccines for the World
New on the Blog
A groundbreaking Ph II study from Aeras and GSK shows new potential for TB vaccines
Urgent Need for New TB Vaccines
Take 1.5 minutes to watch our animated video about why the world urgently needs new TB vaccines to end the epidemic.
Progress in the Pipeline
Together with our partners, we've made significant advances over the past decade using diverse and innovative strategies.
TB is more complex than ever.
TB is becoming more complex and difficult to treat. The rise in multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains is making the disease harder and exponentially more expensive to fight and presents a threat to health in every country.
We are a nonprofit biotech advancing TB vaccines.
With a focus on innovation and impact, Aeras works with leading partners around the world to develop new TB vaccines that will be affordable and accessible to all who need them.
Vaccines are the most cost-effective approach.
TB will not be eliminated without successful new vaccines for both adults and children.
We collaborate within a vast network.
Aeras serves as a catalyst by investing in the world’s most promising TB vaccine candidates and collaborating to strengthen and advance the global pipeline.